Paradox of Bcl-2 (and p53): Why may apoptosis-regulating proteins be irrelevant to cell death?

BioEssays

Volumn 23, Issue 10, 2001, Pages 947-953

  Blagosklonny, Mikhail V ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL 2; PROTEIN P53;

ANIMAL; APOPTOSIS; CELL DEATH; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW;

ANIMALS; APOPTOSIS; CELL DEATH; HUMANS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034794098     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/bies.1135     Document Type: Review

References (84)

1. Mitochondria and apoptosis
2. Dysregulation of apoptosis in cancer
3. Apoptosis in cancer: Cause and cure
4. Life-or-death decisions by the Bcl-2 protein family
5. Apoptotic death of tumor cells correlates with chemosensitivity
6. Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCl Anticancer Drug Screen: Multifactorial relationships with topoisomerase I, protein kinase C, Bcl-2, p53, MDM-2 and caspase pathways
7. bcl-2 protein in non-small-cell lung cancer
8. Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis
9. Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma
10. Bcl-2 protein expression: Association with p53 and prognosis in colorectal cancer
11. Loss of bcl-2 expression in ductal carcinoma in situ of the breast relates to poor histological differentiation and to expression of p53 and c-erbB-2 proteins
12. c-myc, p53 and bcl-2, apoptosis-related genes in infiltrating breast carcinomas: Evidence of a link between bcl-2 protein overexpression and a lower risk of metastasis and death in operable patients
13. Apoptosis and cancer drug targeting
14. p53: Death star
15. Apoptosis, p53, and tumor cell sensitivity to anticancer agents
16. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents
17. Clinical implications of p53 mutations
18. Genetic analysis of chemoresistance in primary murine lymphomas
19. The most unkindest cut of all: On the multiple roles of mammalian caspases
20. Cell death beyond apoptosis
21. Constitutive expression of the machinery for programmed Cell death
22. The p53 response to ionizing radiation in adult and developing murine tissues
23. p53 induction and apoptosis in response to radio- and chemotherapy in vivo is tumor-type-dependent
24. The apoptosis-necrosis paradox. Apoptogenic proteases activated after mitochondrial permeability transition determine the mode of cell death
25. Apoptosis inducing factor (AIF): A phylogenetically old, caspase-independent effector of cell death
26. More than one way to go
27. Non-apoptotic responses to anticancer agents: Mitotic catastrophe, senescence, and the role of p53 and p21
28. Apoptosis without caspases: An inefficient molecular guillotine
29. Nuclear changes in apoptosis
30. Comparison of caspase activation and subcellular localization in HL-60 and K562 cells undergoing etoposide-induced apoptosis
31. Protease inhibitor-induced apoptosis: Accumulation wt p53, p21WAF1/ClP1, and induction of apoptosis are independent markers of proteasome inhibition
32. BCL-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells
33. Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival
34. Differential effects of BCL-2 on survival and proliferation of human B-lymphoma cells following gamma-irradiation
35. Caspase inhibition in camptothecin-treated U-937 cells is coupled with a shift from apoptosis to transient G1 arrest followed by necrotic cell death
36. Paclitaxel-associated multimininucleation is permitted by the inhibition of caspase activation: A potential early step in drug resistance
37. Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells
38. Heat shock protein 70 inhibits apoptosis downstream of cytochrome c release and upstream of caspase-3 activation
39. Kinases: Positive and negative regulators of apoptosis
40. Akt regulates cell survival and apoptosis at a postmitochondrial level
41. BCR-ABL delays apoptosis upstream of procaspase-3 activation
42. Bcl-2 expression restores the leukemogenic potential of a BCR/ABL mutant defective in transformation
43. Cytochrome c deficiency causes embryonic lethality and attenuates stress-induced apoptosis
44. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma
45. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis
46. Caspase-3 is essential for procaspase-9 processing and cisplatin-induced apoptosis of MCF-7 breast cancer cells
47. Cell-specific induction of apoptosis by microinjection of cytochrome c. Bcl-xL has activity independent of cytochrome c release
48. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN
49. Loss of caspase-1 and caspase-3 protein expression in human prostate cancer
50. Defective apoptotic signal transduction pathway downstream of caspase-3 in human B-lymphoma cells: A novel mechanism of nuclear resistance
51. Dead or dying: Necrosis versus apoptosis in caspase-deficient human renal cell carcinoma
52. Biochemical and genetic control of apoptosis: Relevance to normal hematopoiesis and hematological malignancies
53. Developmental regulation of the Bcl-2 protein and susceptibility to cell death in B lymphocytes
54. Elevated expression of Bcl-2 and Bcl-x by intestinal intraepithelial lymphocytes: Resistance to apoptosis by glucocorticoids and irradiation
55. High levels of p26BCL-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells
56. Bcl-2 is phosphorylated and inactivated by ASK1/Jun N-terminal protein kinase pathway normally activated at G2/M
57. Combined effects of aberrant MEK1 activity and BCL2 overexpression on relieving the cytokine dependency of human and murine hematopoietic cells
58. Germ cell suicide: New insights into apoptosis during spermatogenesis
59. Association of bcl-2, bax, bci-xL and interleukin-1 beta-converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia
60. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse
61. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: Correlations with In vitro and In vivo chemoresponses
62. Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo
63. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma
64. Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line
65. Apoptosis: An early event in metastatic inefficiency
66. Bcl-2 accelerates multistep prostate carcinogenesis in vivo
67. BCL-2 proto-oncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell
68. Cellular kinetics and expression of bcl-2 and p53 in ductal carcinoma of the breast
69. p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients
70. Diminished cell proliferation associated with the death-protective activity of Bcl-2
71. Expression level of Bcl-2 determines anti- or proapoptotic function
72. Unwinding the loop of Bcl-2 phosphorylation
73. Apoptosis in cancer
74. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
75. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition
76. Different impact of p53 and p21 on the radiation response of mouse tissues
77. Dissection of the genetic programs of p53-mediated G1 growth arrest and apoptosis: Blocking p53-induced apoptosis unmasks G1 arrest
78. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio
79. p53 alterations in human leukemia-lymphoma cell lines: In vitro artifact or prerequisite for cell immortalization?
80. Surfing the p53 network
81. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer
82. p53 promotes selection for Fas-mediated apoptotic response
83. Sensitivity to Fas-mediated apoptosis in pediatric acute lymphoblastic leukemia is associated with a mutant p53 phenotype and absence of Bcl-2 expression
84. In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug